View Post

Rare Patient Voice: Study Opportunity for Small Cell Lung Cancer Patients & Caregivers

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Web-Assisted Phone Interview Compensation $125 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! …

View Post

Rare Patient Voice: Small Cell Lung Cancer Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Web-Assisted Phone Interview Compensation $100 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others …

View Post

FDA Approves Durvalumab for Frontline Small Cell Lung Cancer

In Clinical Studies News by Barbara Jacoby

By: Gina Columbus From: onclive.com The FDA has approved durvalumab (Imfinzi) for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) for use in combination with standard-of-care chemotherapy, including etoposide plus either carboplatin or cisplatin.1 The approval is based on findings from phase III CASPIAN trial, in which adding the PD-L1 inhibitor to chemotherapy reduced the …

View Post

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer

In Clinical Studies News by Barbara Jacoby

Source: Business Wire From: yahoo.com – 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint) – – Treatment emergent adverse events Grade 3 or higher were reported by 10 of 25 patients (safety as primary endpoint) – Ipsen (Euronext: IPN; ADR: IPSEY) and Servier announced today initial safety and …

View Post

First-in-Class Drug Preserves Blood Counts During Chemotherapy for Lung Cancer

In Clinical Studies News by Barbara Jacoby

By: Beth Fand Incollingo From: curetoday.com Given with each dose of chemotherapy, administration of trilaciclib may temporarily put bone marrow to sleep, helping to prevent fevers, infections and hospital stays in patients with small cell lung cancer, according to study findings presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Side effects from chemotherapy often include nausea, …

View Post

Targeting Innovation in Small Cell Lung Cancer

In Clinical Studies News by Barbara Jacoby

By: Heather Stringer From: curetoday.com After consulting multiple doctors about her ongoing cough and congestion, LeeAnn Devore asked one of her physicians if she might have lung cancer. “He said the symptoms weren’t right,” says Devore, 66, of Magnolia, Texas. Three X-rays in five months confirmed that she had pneumonia in her right lung, yet she wasn’t responding to traditional …

View Post

New therapeutic targets for small cell lung cancer identified – Science Daily

In In The News by Barbara Jacoby

Source: UT Southwestern Medical Center From: sciencedaily.com UT Southwestern Medical Center researchers have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming. The new findings identify ASCL1 as an important therapeutic target for small cell lung cancer, for which …

Could Antidepressant Combat Lethal Lung Cancer?

In In The News by Barbara Jacoby

As posted on Drugs.com An older and little-used class of antidepressants may help combat a particularly deadly form of lung cancer, according to a new study. Using a unique computer program, researchers from the Stanford University School of Medicine identified tricyclic antidepressants as a potential treatment for small cell lung cancer. This class of drugs was introduced decades ago and …

Discovery May Help Pinpoint Risk of Lung Cancer Returning After Surgery

In In The News by Barbara Jacoby

From Drugs.com Certain characteristics of tumors in lung cancer patients are associated with a strong risk of cancer recurrence after surgery, according to a new study. The researchers said these findings could help identify patients who will benefit from more extensive lung surgery, potentially reducing the risk of lung cancer recurrence by 75 percent. It could also help identify patients …

More Bridges, More Options in Cancer Treatment – ASCO 2013 Wrap Up

In In The News, Uncategorized by Barbara Jacoby

POSTED IN Blog, Healthcare, Pharma The ASCO 2013 Annual Meeting has come to a close and the over 25,000 attendees have returned home armed with new ideas around the advances in cancer treatment. The conference highlighted immunotherapies, breakthrough drugs and difficult issues facing the oncology community. Immunotherapies were the hottest new topic in oncotherapy development, you expect to hear much …